Meeting to be held in New York on September 26 at 12:15 pm hosted by Oppenheimer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron, Sanofi announce FDA acceptance for Priority Review of Dupixent sBLA
- Regeneron management to meet with Oppenheimer
- Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
- Regeneron completes Decibel acquisition, any guidance update to be in Q3
- Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss